TCRT - Alaunos Therapeutics, Inc.
Previous close
1.7
-0.150 -8.824%
Share volume: 19,657
Last Updated: Fri 10 Jan 2025 10:00:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.44%
PREVIOUS CLOSE
CHG
CHG%
$1.85
-0.15
-0.08%
Fundamental analysis
7%
Profitability
0%
Dept financing
23%
Liquidity
48%
Performance
0%
Performance
5 Days
-8.11%
1 Month
-10.53%
3 Months
-18.27%
6 Months
150.00%
1 Year
-13.15%
2 Year
113.22%
Key data
Stock price
$1.70
DAY RANGE
$1.67 - $1.82
52 WEEK RANGE
$0.62 - $5.62
52 WEEK CHANGE
-$13.15
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Kevin S. Boyle
Region: US
Website: alaunos.com
Employees: 40
IPO year: 2006
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: alaunos.com
Employees: 40
IPO year: 2006
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR. The company was formerly known as ZIOPHARM Oncology, Inc.
Recent news